The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessAbstract
This ESMO Clinical Practice Guidelines provide updated state-of-the-art recommendations on management of thyroid cancer (diagnosis, treatment and follow-up), compiled by a multidisciplinary author panel and accompanied by level of evidence and grade of recommendation, depending on the strength of supporting data and magnitude of benefit from particular interventions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 2×
“1 are used to define target lesions and measure responses to systemic treatment [94].”
BackgroundHaugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Self-citationThe Bethesda System for Reporting Thyroid Cytopathology
Cibas, E. S., & Ali, S. Z. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcpphlwmi3jv4la · Cited by 2,040
Pacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,976
Durante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J. D., De Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,675
Self-citationBrose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update
Oktay, K., Harvey, B. E., Partridge, A. H., Quinn, G. P., Reinecke, J., Taylor, H. S., Wallace, W. H., Wang, E. T., & Loren, A. W. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.1914 · Cited by 1,486
Nikiforov, Y. E., Seethala, R. R., Tallini, G., Baloch, Z. W., Basolo, F., Thompson, L. D. R., Barletta, J. A., Wenig, B. M., Al Ghuzlan, A., Kakudo, K., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0386 · Cited by 1,404
Self-citationGenomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis
Vaccarella, S., Franceschi, S., Bray, F., Wild, C. P., Plummer, M., & Dal Maso, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1604412 · Cited by 1,145
The changing incidence of thyroid cancer
Kitahara, C. M., & Sosa, J. A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.110 · Cited by 1,051
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
Tuttle, R. M., Tala, H., Shah, J., Leboeuf, R., Ghossein, R., Gonen, M., Brokhin, M., Omry, G., Fagin, J. A., & Shaha, A. (2010) · Thyroid · doi:10.1089/thy.2010.0178 · Cited by 924
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., Cabanillas, M. E., Urbanowitz, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 892
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
Guidelines for radioiodine therapy of differentiated thyroid cancer
Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0883-1 · Cited by 727
Extent of Surgery Affects Survival for Papillary Thyroid Cancer
Bilimoria, K. Y., Bentrem, D. J., Ko, C. Y., Stewart, A. K., Winchester, D. P., Talamonti, M. S., & Sturgeon, C. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e31814697d9 · Cited by 697
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
Schlumberger, M., Catargi, B., Borget, I., Deandreis, D., Zerdoud, S., Bridji, B., Bardet, S., Leenhardt, L., Bastie, D., Schvartz, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108586 · Cited by 684
Self-citationESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Volante, M., Collini, P., Nikiforov, Y. E., Sakamoto, A., Kakudo, K., Katoh, R., Lloyd, R. V., LiVolsi, V. A., Papotti, M., Sobrinho-Simoes, M., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3180309e6a · Cited by 619
Self-citationAblation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer
Mallick, U., Harmer, C., Yap, B., Wadsley, J., Clarke, S., Moss, L., Nicol, A., Clark, P. M., Farnell, K., McCready, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109589 · Cited by 615
Self-citationRobbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gonen, M., Strauss, H. W., Tuttle, R. M., Drucker, W., & Larson, S. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1534 · Cited by 587
Leboulleux, S., Girard, E., Rose, M., Travagli, J. P., Sabbah, N., Caillou, B., Hartl, D. M., Lassau, N., Baudin, E., & Schlumberger, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0444 · Cited by 539
Self-citationGenetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
Pozdeyev, N., Gay, L. M., Sokol, E. S., Hartmaier, R., Deaver, K. E., Davis, S., French, J. D., Borre, P. V., LaBarbera, D. V., Tan, A.-C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0373 · Cited by 533
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470 · cited 1×
“7 Cabozantinib Brose MS, 2018 [105] 35 54 Not reached yet Motesanib Sherman SI, 2008 [106] 93 14 9 Nintedanib Schlumberger M, 2018 [107] 70 0 3.”
Shimaoka, K., Schoenfeld, D. A., Dewys, W. D., Creech, R. H., & Deconti, R. (1985) · Cancer · doi:10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e · Cited by 464
Pacini, F., Ladenson, P. W., Schlumberger, M., Driedger, A., Luster, M., Kloos, R. T., Sherman, S., Haugen, B., Corone, C., Molinaro, E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1651 · Cited by 450
Self-citationAdam, M. A., Pura, J., Gu, L., Dinan, M. A., Tyler, D. S., Reed, S. D., Scheri, R., Roman, S. A., & Sosa, J. A. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000925 · Cited by 427
Selective RET kinase inhibition for patients with RET-altered cancers
Subbiah, V., Velcheti, V., Tuch, B. B., Ebata, K., Busaidy, N. L., Cabanillas, M. E., Wirth, L. J., Stock, S., Smith, S., Lauriault, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy137 · Cited by 425
Carr, L. L., Mankoff, D. A., Goulart, B. H., Eaton, K. D., Capell, P. T., Kell, E. M., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 422
Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C., McIver, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70203-5 · Cited by 421
Tuttle, R. M., Ahuja, S., Avram, A. M., Bernet, V. J., Bourguet, P., Daniels, G. H., Dillehay, G., Draganescu, C., Flux, G., Führer, D., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0597 · Cited by 413
Barbet, J., Campion, L., Kraeber-Bodéré, F., & Chatal, J.-F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0044 · Cited by 407
Leenhardt, L., Erdogan, M. F., Hegedus, L., Mandel, S. J., Paschke, R., Rago, T., & Russ, G. (2013) · European Thyroid Journal · doi:10.1159/000354537 · Cited by 404
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules
Nikiforova, M. N., Mercurio, S., Wald, A. I., Barbi de Moura, M., Callenberg, K., Santana‐Santos, L., Gooding, W. E., Yip, L., Ferris, R. L., & Nikiforov, Y. E. (2018) · Cancer · doi:10.1002/cncr.31245 · Cited by 396
RUEGEMER, J. J., HAY, I. D., BERGSTRALH, E. J., RYAN, J. J., OFFORD, K. P., & GORMAN, C. A. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-501 · Cited by 389
Brose, M. S., Cabanillas, M. E., Cohen, E. E. W., Wirth, L. J., Riehl, T., Yue, H., Sherman, S. I., & Sherman, E. J. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30166-8 · Cited by 388
Biomarker-Based Risk Stratification for Previously Untreated Medullary Thyroid Cancer
Machens, A., & Dralle, H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2368 · Cited by 385
Definition and management of radioactive iodine-refractory differentiated thyroid cancer
Schlumberger, M., Brose, M., Elisei, R., Leboulleux, S., Luster, M., Pitoia, F., & Pacini, F. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70215-8 · Cited by 377
Self-citationHauch, A., Al-Qurayshi, Z., Randolph, G., & Kandil, E. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3846-8 · Cited by 377
Leboulleux, S., Bastholt, L., Krause, T., de la Fouchardiere, C., Tennvall, J., Awada, A., Gómez, J. M., Bonichon, F., Leenhardt, L., Soufflet, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70335-2 · Cited by 375
Self-citationCostante, G., Meringolo, D., Durante, C., Bianchi, D., Nocera, M., Tumino, S., Crocetti, U., Attard, M., Maranghi, M., Torlontano, M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1590 · Cited by 372
Self-citationAnaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment
Nagaiah, G., Hossain, A., Mooney, C. J., Parmentier, J., & Remick, S. C. (2011) · Journal of Oncology · doi:10.1155/2011/542358 · Cited by 317
Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2017) · JAMA · doi:10.1001/jama.2017.4011 · Cited by 313
Ain, K. B., Egorin, M. J., DeSimone, P. A., & Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group* (2000) · Thyroid · doi:10.1089/thy.2000.10.587 · Cited by 295
Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials
Ito, Y., Miyauchi, A., & Oda, H. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.03.004 · Cited by 295
Prophylactic central neck dissection for papillary thyroid cancer
Barczyński, M., Konturek, A., Stopa, M., & Nowak, W. (2013) · Journal of British Surgery · doi:10.1002/bjs.8985 · Cited by 281
Castagna, M. G., Maino, F., Cipri, C., Belardini, V., Theodoropoulou, A., Cevenini, G., & Pacini, F. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0466 · Cited by 275
Laure Giraudet, A., Al Ghulzan, A., Aupérin, A., Leboulleux, S., Chehboun, A., Troalen, F., Dromain, C., Lumbroso, J., Baudin, E., & Schlumberger, M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0667 · Cited by 272
Self-citationManagement of thyroid cancer: United Kingdom National Multidisciplinary Guidelines
Mitchell, A. L., Gandhi, A., Scott-Coombes, D., & Perros, P. (2016) · The Journal of Laryngology & Otology · doi:10.1017/s0022215116000578 · Cited by 270
Miyauchi, A., Kudo, T., Miya, A., Kobayashi, K., Ito, Y., Takamura, Y., Higashiyama, T., Fukushima, M., Kihara, M., Inoue, H., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0355 · Cited by 265
Agrawal, N., Jiao, Y., Sausen, M., Leary, R., Bettegowda, C., Roberts, N. J., Bhan, S., Ho, A. S., Khan, Z., Bishop, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2703 · Cited by 255
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Dunn, L. A., Sherman, E. J., Baxi, S. S., Tchekmedyian, V., Grewal, R. K., Larson, S. M., Pentlow, K. S., Haque, S., Tuttle, R. M., Sabra, M. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01478 · Cited by 250
Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer
McGriff, N. J., Csako, G., Gourgiotis, L., Guthrie, L. C., Pucino, F., & Sarlis, N. J. (2002) · Annals of Medicine · doi:10.1080/078538902321117760 · Cited by 247
Torlontano, M., Attard, M., Crocetti, U., Tumino, S., Bruno, R., Costante, G., D’Azzò, G., Meringolo, D., Ferretti, E., Sacco, R., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031521 · Cited by 242
Self-citationSouth Korea’s Thyroid-Cancer “Epidemic” — Turning the Tide
Ahn, H. S., & Welch, H. G. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1507622 · Cited by 240 · cited 1×
“The resulting overdiagnosis has invariably been accompanied by overtreatment [5].”
BackgroundSchlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M. C., Niederle, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx479 · Cited by 240
Spencer, C. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1740 · Cited by 235
Momesso, D. P., Vaisman, F., Yang, S. P., Bulzico, D. A., Corbo, R., Vaisman, M., & Tuttle, R. M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4290 · Cited by 231
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer
Falchook, G. S., Millward, M., Hong, D., Naing, A., Piha-Paul, S., Waguespack, S. G., Cabanillas, M. E., Sherman, S. I., Ma, B., Curtis, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0123 · Cited by 227
De Crevoisier, R., Baudin, E., Bachelot, A., Leboulleux, S., Travagli, J.-P., Caillou, B., & Schlumberger, M. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.05.032 · Cited by 221
Self-citationBrassard, M., Borget, I., Edet-Sanson, A., Giraudet, A.-L., Mundler, O., Toubeau, M., Bonichon, F., Borson-Chazot, F., Leenhardt, L., Schvartz, C., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2708 · Cited by 220
Pacini, F., Basolo, F., Bellantone, R., Boni, G., Cannizzaro, M. A., De Palma, M., Durante, C., Elisei, R., Fadda, G., Frasoldati, A., et al. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0884-2 · Cited by 216
Self-citationInterobserver agreement of various thyroid imaging reporting and data systems
Grani, G., Lamartina, L., Cantisani, V., Maranghi, M., Lucia, P., & Durante, C. (2018) · Endocrine Connections · doi:10.1530/ec-17-0336 · Cited by 210
Self-citationLenvatinib for Anaplastic Thyroid Cancer
Tahara, M., Kiyota, N., Yamazaki, T., Chayahara, N., Nakano, K., Inagaki, L., Toda, K., Enokida, T., Minami, H., Imamura, Y., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00025 · Cited by 205
Grani, G., Lamartina, L., Durante, C., Filetti, S., & Cooper, D. S. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30325-x · Cited by 203
Self-citationBrose, M. S., Worden, F. P., Newbold, K. L., Guo, M. D., & Hurria, A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6472 · Cited by 200
Self-citationAsioli, S., Erickson, L. A., Sebo, T. J., Zhang, J., Jin, L., Thompson, G. B., & Lloyd, R. V. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181c46677 · Cited by 197
Lamartina, L., Durante, C., Filetti, S., & Cooper, D. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3882 · Cited by 196
Self-citationCarhill, A. A., Litofsky, D. R., Ross, D. S., Jonklaas, J., Cooper, D. S., Brierley, J. D., Ladenson, P. W., Ain, K. B., Fein, H. G., Haugen, B. R., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1346 · Cited by 184
Meijer, J. A. A., Le Cessie, S., Van Den Hout, W. B., Kievit, J., Schoones, J. W., Romijn, J. A., & Smit, J. W. A. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03666.x · Cited by 180
Deandreis, D., Al Ghuzlan, A., Leboulleux, S., Lacroix, L., Garsi, J. P., Talbot, M., Lumbroso, J., Baudin, E., Caillou, B., Bidart, J. M., et al. (2011) · Endocrine Related Cancer · doi:10.1677/erc-10-0233 · Cited by 177
Self-citationMiyauchi, A., Kudo, T., Ito, Y., Oda, H., Sasai, H., Higashiyama, T., Fukushima, M., Masuoka, H., Kihara, M., & Miya, A. (2018) · Surgery · doi:10.1016/j.surg.2017.03.028 · Cited by 176
Moon, S., Song, Y. S., Kim, Y. A., Lim, J. A., Cho, S. W., Moon, J. H., Hahn, S., Park, D. J., & Park, Y. J. (2017) · Thyroid · doi:10.1089/thy.2016.0350 · Cited by 173
Schlumberger, M., Leboulleux, S., Catargi, B., Deandreis, D., Zerdoud, S., Bardet, S., Rusu, D., Godbert, Y., Buffet, C., Schvartz, C., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30113-x · Cited by 173
Self-citationDrug induced osteonecrosis of the jaw
Hamadeh, I. S., Ngwa, B. A., & Gong, Y. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.007 · Cited by 171
Interventions for the treatment of metastatic extradural spinal cord compression in adults
George, R., Sundararaj, J. J., Govindaraj, R., Chacko, A. G., & Tharyan, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006716.pub3 · Cited by 165
Durante, C., Montesano, T., Attard, M., Torlontano, M., Monzani, F., Costante, G., Meringolo, D., Ferdeghini, M., Tumino, S., Lamartina, L., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1123 · Cited by 162
Self-citationGrani, G., & Fumarola, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1098 · Cited by 161
Vuong, H. G., Altibi, A. M. A., Duong, U. N. P., & Hassell, L. A. (2017) · Clinical Endocrinology · doi:10.1111/cen.13413 · Cited by 154
Chen, L., Wu, Y., Lee, C., Chen, H., Loh, E., & Tam, K. (2018) · World Journal of Surgery · doi:10.1007/s00268-018-4547-4 · Cited by 154
Dehbi, H., Mallick, U. K., Wadsley, J., Newbold, K. L., Harmer, C., & Hackshaw, A. K. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30306-1 · Cited by 152
Self-citationSosa, J. A., Elisei, R., Jarząb, B., Balkissoon, J., Lu, S.-P., Bal, C., Marur, S., Gramza, A. W., Ben‐Yosef, R., Gitlitz, B. J., et al. (2013) · Thyroid · doi:10.1089/thy.2013.0078 · Cited by 151
Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls
Costante, G., Durante, C., Francis, Z., Schlumberger, M. J., & Filetti, S. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet1023 · Cited by 143
Self-citationManagement of advanced medullary thyroid cancer
Hadoux, J., Pacini, F., Tuttle, R. M., & Schlumberger, M. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00337-x · Cited by 142
Sugitani, I., & Fujimoto, Y. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0161 · Cited by 141
Cabanillas, M. E., de Souza, J. A., Geyer, S. M., Wirth, L. J., Menefee, M. E., Liu, S. V., Shah, K. B., Wright, J., & Shah, M. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0226 · Cited by 139
Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice
Berdelou, A., Borget, I., Godbert, Y., Nguyen, T., Garcia, M.-E., Chougnet, C., Ferru, A., Buffet, C., Chabre, O., Huillard, O., et al. (2017) · Thyroid · doi:10.1089/thy.2017.0205 · Cited by 129
Self-citationLocati, L. D., Licitra, L. F., Agate, L., Ou, S. I., Boucher, A., Jarząb, B., Qin, S., Kane, M. A., Wirth, L. J., Chen, C., et al. (2014) · Cancer · doi:10.1002/cncr.28766 · Cited by 124
Self-citationIbrahimpašić, T., Xu, B., Landa, I., Doğan, S., Middha, S., Seshan, V., Deraje, S., Carlson, D. L., Migliacci, J. C., Knauf, J. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1183 · Cited by 124
Hughes, D. T., Rosen, J. E., Evans, D. B., Grubbs, E. G., Wang, T. S., & Solórzano, C. C. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6528-0 · Cited by 124
Elisei, R., Alevizaki, M. K., Conte‐Devolx, B., Frank‐Raue, K., Leite, V. A. P. H., & Williams, G. R. (2012) · European Thyroid Journal · doi:10.1159/000346174 · Cited by 122
Giovanella, L., CLARK, P. M. S., Chiovato, L., Duntas, L. H., Elisei, R., Feldt‐Rasmussen, U., Leenhardt, L., Luster, M., Schalin‐Jäntti, C., Schott, M., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0148 · Cited by 115
Tahara, M., Brose, M. S., Wirth, L. J., Suzuki, T., Miyagishi, H., Fujino, K., Dutcus, C. E., & Gianoukakis, A. G. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.002 · Cited by 112
Verburg, F. A., Aktolun, C., Chiti, A., Frangos, S., Giovanella, L., Hoffmann, M., Iakovou, I. P., Mihailovic, J. M., Krause, B. J., Langsteger, W., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3327-3 · Cited by 111
Haddad, R. I., Schlumberger, M. J., Wirth, L. J., Sherman, E. J., Shah, M. H., Robinson, B. G., Dutcus, C. E., Teng, A., Gianoukakis, A. G., & Sherman, S. I. (2017) · Endocrine · doi:10.1007/s12020-017-1233-5 · Cited by 111
Maso, L. D., Tavilla, A., Pacini, F., Serraino, D., van Dijk, B. A. C., Chirlaque, M., Capocaccia, R., Larrañaga, N., Colonna, M., Agius, D., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.023 · Cited by 110
The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers
Leboulleux, S., Schroeder, P. R., Schlumberger, M. J., & Ladenson, P. W. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0402 · Cited by 109
Self-citationDurante, C., Attard, M., Torlontano, M., Ronga, G., Monzani, F., Costante, G., Ferdeghini, M., Tumino, D., Meringolo, D., Bruno, R., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0762 · Cited by 107
Self-citationDeandreis, D., Rubino, C., Tala, H., Leboulleux, S., Terroir, M., Baudin, É., Larson, S. M., Fagin, J. A., Schlumberger, M. J., & Tuttle, R. M. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.179606 · Cited by 103
Self-citationApproach to the Thyroid Cancer Patient with Bone Metastases
Wexler, J. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1996 · Cited by 100
Sherman, E. J., Lim, S. H., Ho, A. L., Ghossein, R. A., Fury, M. G., Shaha, A. R., Rivera, M., Lin, O., Wolden, S. L., Lee, N. Y., et al. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.09.004 · Cited by 99
Sabra, M. M., Sherman, E. J., & Tuttle, R. M. (2017) · Cancer · doi:10.1002/cncr.30690 · Cited by 96
Robinson, B. G., Schlumberger, M. J., Wirth, L. J., Dutcus, C. E., Song, J., Taylor, M. H., Kim, S., Krzyzanowska, M. K., Capdevila, J., Sherman, S. I., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3989 · Cited by 95
Park, S., Kim, W. G., Song, E., Oh, H., Kim, M., Kwon, H., Jeon, M. J., Kim, T. Y., Shong, Y. K., & Kim, W. B. (2016) · Thyroid · doi:10.1089/thy.2016.0477 · Cited by 95
Romei, C., Casella, F., Tacito, A., Bottici, V., Valerio, L., Viola, D., Cappagli, V., Matrone, A., Ciampi, R., Piaggi, P., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103833 · Cited by 94
Zhao, W., Luo, H., Zhou, Y., Dai, W., & Zhu, J. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.07.008 · Cited by 93
Leveraging the immune system to treat advanced thyroid cancers
French, J. D., Bible, K. C., Spitzweg, C., Haugen, B. R., & Ryder, M. M. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30277-7 · Cited by 81
Systematic review of site distribution of bone metastases in differentiated thyroid cancer
Osorio, M., Moubayed, S. P., Su, H. K., & Urken, M. L. (2017) · Head & Neck · doi:10.1002/hed.24655 · Cited by 74
Kwon, J., Kim, B. H., Jung, H., Bešič, N., Sugitani, I., & Wu, H. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.015 · Cited by 67
Lamartina, L., Grani, G., Biffoni, M., Giacomelli, L., Costante, G., Lupo, S., Maranghi, M., Plasmati, K., Sponziello, M., Trulli, F., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1440 · Cited by 64
Self-citationThyroid Cancer Patients With No Evidence of Disease: The Need for Repeat Neck Ultrasound
Grani, G., Ramundo, V., Falcone, R., Lamartina, L., Montesano, T., Biffoni, M., Giacomelli, L., Sponziello, M., Verrienti, A., Schlumberger, M. J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00962 · Cited by 61
Self-citationNascimento, C., Borget, I., Ghuzlan, A. A., Deandreis, D., Hartl, D. M., Lumbroso, J., Berdelou, A., Lussey‐Lepoutre, C., Mirghani, H., Baudin, É., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0320 · Cited by 56
Self-citationChemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer
Hadoux, J., & Schlumberger, M. J. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.04.009 · Cited by 56
Iten, F., Müller-Stich, B. P., Schindler, C., Rasch, H. F., Rochlitz, C. F., Oertli, D., Maëcke, H. R., Müller‐Brand, J., & Walter, M. A. (2009) · Cancer · doi:10.1002/cncr.24272 · Cited by 55
Mazziotti, G., Formenti, A. M., Panarotto, M. B., Arvat, E., Chiti, A., Cuocolo, A., Dottorini, M. E., Durante, C., Agate, L., Filetti, S., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1455-6 · Cited by 52
Self-citationCapdevila, J., Newbold, K. L., Licitra, L. F., Popovtzer, A., Moreso, F., Zamorano, J. L., Kreissl, M. C., Aller, J., & Grande, E. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.019 · Cited by 48
Self-citationCrocetti, U., Durante, C., Attard, M., Maniglia, A., Tumino, D., Bruno, R., Bonfitto, N., Dicembrino, F., Varraso, A., Meringolo, D., et al. (2008) · Thyroid · doi:10.1089/thy.2008.0160 · Cited by 41
Self-citationAngell, T. E., Spencer, C. A., Rubino, B., Nicoloff, J. T., & LoPresti, J. S. (2014) · Thyroid · doi:10.1089/thy.2013.0691 · Cited by 39
Recent advances and emerging therapies in anaplastic thyroid carcinoma
Cabanillas, M. E., Zafereo, M., Williams, M. D., Ferrarotto, R., Dadu, R., Gross, N. D., Gunn, G. B., Skinner, H. D., Cote, G. J., Grosu, H. B., et al. (2018) · F1000Research · doi:10.12688/f1000research.13124.1 · Cited by 25
Stroma Targeting Nuclear Imaging and Radiopharmaceuticals
Shetty, D., Jeong, J. M., & Shim, H. (2012) · International Journal of Molecular Imaging · doi:10.1155/2012/817682 · Cited by 18
Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer
Bastholt, L., Kreissl, M. C., Führer, D., Maia, A. L., Locati, L. D., Maciel, L. M. Z., Wu, Y., Heller, K. N., Webster, A., & Elisei, R. (2016) · European Thyroid Journal · doi:10.1159/000448919 · Cited by 13
Self-citation
Research works printed but not linked: 34
- 2019, European Network of Cancer Registries Factsheets
- Maletta, 2016, Cytological features of “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” and their correlation with tumor histology, Hum Pathol, 54, 134, 10.1016/j.humpath.2016.03.014 · doi:10.1016/j.humpath.2016.03.014
- Williams, 2000, Guest editorial: two proposals regarding the terminology of thyroid tumors, Int J Surg Pathol, 8, 181, 10.1177/106689690000800304 · doi:10.1177/106689690000800304
- Randolph, 2011, The surgical management of goiter: Part II. Surgical treatment and results, Laryngoscope, 121, 68, 10.1002/lary.21091 · doi:10.1002/lary.21091
- Lamartina, 2018, Recent advances in managing differentiated thyroid cancer, F1000Res, 7, 86., 10.12688/f1000research.12811.1 · DOI
- Lamartina, 2016, ENDOCRINE TUMOURS: imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach, Eur J Endocrinol, 175, R185, 10.1530/EJE-16-0088 · doi:10.1530/eje-16-0088
- Robbins, 2008, The value of positron emission tomography (PET) in the management of patients with thyroid cancer, Best Pract Res Clin Endocrinol Metab, 22, 1047, 10.1016/j.beem.2008.10.001 · doi:10.1016/j.beem.2008.10.001
- Terroir, 2017, The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 44, 638, 10.1007/s00259-016-3551-x · doi:10.1007/s00259-016-3551-x
- Choksi, 2017, Skeletal complications and mortality in thyroid cancer: a population-based study, J Clin Endocrinol Metab, 102, 1254, 10.1210/jc.2016-3906 · doi:10.1210/jc.2016-3906
- Drost, 2017, Efficacy of postoperative radiation treatment for bone metastases in the extremities, Radiother Oncol, 124, 45, 10.1016/j.radonc.2017.05.010 · doi:10.1016/j.radonc.2017.05.010
- Deschamps, 2014, Percutaneous ablation of bone tumors, Diagn Interv Imaging, 95, 659, 10.1016/j.diii.2014.04.004 · doi:10.1016/j.diii.2014.04.004
- Deschamps, 2016, Percutaneous osteosynthesis in the pelvis in cancer patients, Eur Radiol, 26, 1631, 10.1007/s00330-015-3971-1 · doi:10.1007/s00330-015-3971-1
- de Baere, 2015, Interventional oncology for liver and lung metastases from colorectal cancer: the current state of the art, Diagn Interv Imaging, 96, 647, 10.1016/j.diii.2015.04.004 · DOI
- Venkatanarasimha, 2017, Radioembolisation of hepatocellular carcinoma: a primer, Clin Radiol, 72, 1002, 10.1016/j.crad.2017.07.021 · doi:10.1016/j.crad.2017.07.021
- Balmelli, 2018, Lenvatinib in advanced radioiodine-refractory thyroid cancer—a retrospective analysis of the Swiss Lenvatinib Named Patient Program, J Cancer, 9, 250, 10.7150/jca.22318 · doi:10.7150/jca.22318
- Brose, 2018, A phase 2 trial of cabozantinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma in the first-line setting, Int J Radiat Oncol Biol Phys, 100, 1311, 10.1016/j.ijrobp.2017.12.028 · doi:10.1016/j.ijrobp.2017.12.028
- Schlumberger, 2018, A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209, J Clin Oncol, 36, 6021., 10.1200/JCO.2018.36.15_suppl.6021 · doi:10.1200/jco.2018.36.15_suppl.6021
- Bogsrud, 2008, 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma, Thyroid, 18, 713, 10.1089/thy.2007.0350 · doi:10.1089/thy.2007.0350
- Sugitani, 2018, Management of anaplastic thyroid carcinoma: the fruits from the ATC research consortium of Japan, J Nippon Med Sch, 85, 18, 10.1272/jnms.2018_85-3 · doi:10.1272/jnms.2018_85-3
- Baek, 2017, Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012, Head Neck, 39, 133, 10.1002/hed.24559 · doi:10.1002/hed.24559
- Ito, 2012, Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors, Head Neck, 34, 230, 10.1002/hed.21721 · doi:10.1002/hed.21721
- Bhatia, 2010, Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy, Head Neck, 32, 829, 10.1002/hed.21257 · doi:10.1002/hed.21257
- Mohebati, 2014, Anaplastic thyroid carcinoma: a 25-year single-institution experience, Ann Surg Oncol, 21, 1665, 10.1245/s10434-014-3545-5 · doi:10.1245/s10434-014-3545-5
- Pezzi, 2017, Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base, Cancer, 123, 1653, 10.1002/cncr.30493 · doi:10.1002/cncr.30493
- Wang, 2006, Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens, Cancer, 107, 1786, 10.1002/cncr.22203 · doi:10.1002/cncr.22203
- Dandekar, 2009, Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis, Int J Radiat Oncol Biol Phys, 74, 518, 10.1016/j.ijrobp.2008.08.016 · doi:10.1016/j.ijrobp.2008.08.016
- Foote, 2011, Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy, Thyroid, 21, 25, 10.1089/thy.2010.0220 · doi:10.1089/thy.2010.0220
- Wirth, 2018, Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer, J Clin Oncol, 36, 6024, 10.1200/JCO.2018.36.15_suppl.6024 · doi:10.1200/jco.2018.36.15_suppl.6024
- Moley, 1999, Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection, Ann Surg, 229, 880, 10.1097/00000658-199906000-00016 · doi:10.1097/00000658-199906000-00016
- Treglia, 2012, PET imaging in recurrent medullary thyroid carcinoma, Int J Mol Imaging, 2012, 1
- Romero-Lluch, 2017, Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff, Eur J Nucl Med Mol Imaging, 44, 2004, 10.1007/s00259-017-3759-4 · doi:10.1007/s00259-017-3759-4
- Bodei, 2004, Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas, Cancer Biother Radiopharm, 19, 65, 10.1089/108497804773391694 · doi:10.1089/108497804773391694
- Fox, 2013, Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma, Clin Cancer Res, 19, 4239, 10.1158/1078-0432.CCR-13-0071 · doi:10.1158/1078-0432.ccr-13-0071
- Trimboli, 2018, Efficacy of vandetanib in treating locally advanced or metastatic medullary thyroid carcinoma according to RECIST criteria: a systematic review and meta-analysis, Front Endocrinol (Lausanne), 9, 224., 10.3389/fendo.2018.00224 · doi:10.3389/fendo.2018.00224
Cited by
Chen, D. W., Lang, B. H. H., McLeod, D. S. A., Newbold, K., & Haymart, M. R. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00020-x · Cited by 590
Self-citationTyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., & Sounni, N. E. (2020) · Cancers · doi:10.3390/cancers12030731 · Cited by 515
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C. C., Cabanillas, M. E., Boran, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.014 · Cited by 357
Current practice in patients with differentiated thyroid cancer
Schlumberger, M., & Leboulleux, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00448-z · Cited by 342
Self-citationContemporary Thyroid Nodule Evaluation and Management
Grani, G., Sponziello, M., Pecce, V., Ramundo, V., & Durante, C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa322 · Cited by 317
Self-citation
Metadata
- Authors
- Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 30
- Issue
- 12
- Pages
- 1856-1883
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2975387808
- Cited by
- 1,200
- References
- 131
- FWCI
- 67.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 366 d)
- Funders
- ESMO
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.